AI SRMA Suite
India's first AI-guided Systematic Review & Meta-Analysis platform. From PICO to PRISMA 2020 flow diagram — 10 databases, Cochrane-compliant, guided by AI.
- Unlimited systematic reviews — lifetime access
- PICO / PIRO / PFO-T framework-aware protocol builder
- Reproducible search strategies for 10 databases
- One-click auto-import from 5 free databases
- AI-assisted title/abstract screening
- Cochrane RoB 2 / ROBINS-I / QUADAS-2 assessment
One-time payment · lifetime access · unlimited reviews · no hidden fees.
Already a member? Sign in →Limited-time launch pricing — regular ₹76,000 applies after the launch period.
Everything you need, end-to-end
10 guided steps from topic discovery to a publishable manuscript — every step mapped to Cochrane Handbook sections, PRISMA 2020 items, and GRADE guidance.
Topic & Framework
PICO, PIRO, or PFO-T — the right framework for intervention, diagnostic, or prognostic reviews.
Protocol Builder
PROSPERO-ready protocol with eligibility criteria, outcome type, analysis model.
Search Strategy Builder
10 databases with native-syntax queries + PRISMA-S 2021 methodology export.
AI Screening
Title/abstract screening with a model that learns from your decisions.
Data Extraction
Structured extraction with custom templates for any study design.
Risk of Bias
Cochrane RoB 2 for RCTs, ROBINS-I for observational, QUADAS-2 for diagnostic — auto-picked for you.
Meta-Analysis
Forest plots, funnel plots, heterogeneity (I², τ²), fixed/random effects, subgroup & sensitivity.
GRADE Assessment
Certainty of evidence across all five domains.
PRISMA 2020 Flow
Canonical four-box diagram — Page et al., BMJ 2021;372:n71.
Publication-quality outputs — live, in the Suite
Every artefact below is a real output from the AI SRMA Suite: same SVG engine, same calculator, same certificate generator that emails to learners. Browse the eight signature outputs your manuscript and submission package will contain.
PRISMA 2020 Flow Diagram
The canonical four-stage flow diagram every peer-reviewed systematic review reproduces: Identification → Screening → Eligibility → Included. The Suite renders it live as you screen, with auto-counted exclusion reasons. Drop it straight into your manuscript.
- Records identified — from each database with auto counts
- Removed before screening — duplicates, ineligibles, automation
- Screening — title/abstract + full-text exclusions with reasons
- Included — final synthesis + meta-analysis pool
Reference: Page MJ et al. The PRISMA 2020 statement. BMJ 2021;372:n71
DerSimonian-Laird random-effects · Cochrane Handbook v6.4 · Reported per PRISMA 2020 + SAMPL
Forest Plot with Summary Diamond
The visual signature of every meta-analysis. Each row is one study with risk ratio + 95% CI; box size reflects inverse-variance weight. The gold diamond at the bottom is the random-effects pooled estimate — if it crosses the null line, the result is not significant.
- Logarithmic x-axis — symmetric around RR = 1
- Study boxes — sized by inverse-variance weight
- Summary diamond — DerSimonian-Laird random-effects
- Heterogeneity stats — τ², Cochran Q, I² with interpretation
- Prediction interval — likely effect in a new study
LogFrame Matrix
The canonical 4×4 logical framework every bilateral donor, UN agency, and major foundation expects. Goal · Purpose · Outputs · Activities along rows; Narrative · OVIs · Means of Verification · Assumptions along columns. The wizard generates this in minutes.
- Vertical logic — IF activities → THEN outputs → THEN purpose → THEN goal
- Horizontal logic — every row has indicators + verification + assumptions
- Donor variants — EU/FCDO 4×4 · UNDP 5-row · 1-page compact
| Level | Narrative summary | OVIs | MoV | Assumptions |
|---|---|---|---|---|
| Goal Long-term impact |
Reduced maternal morbidity from hypertensive disorders in Bilaspur district. | MMR from hypertensive disorders: 22 → ≤15/100,000 by 2030 | MDSR annual report; HMIS extract | State policy stable; no new contraindications emerge. |
| Purpose Project outcome |
≥70% of eligible nulliparous ANC attendees receive aspirin prophylaxis before 16 wks GA. | % screened at booking: 8% → ≥70% by 2029. % screen-positive initiating aspirin <16 wks: 4% → ≥85%. | ANC register audit (Q); pharmacy data | Coverage translates to reduced PE per ASPRE 2017. |
| Outputs Deliverables |
O1: SOP adopted district-wide. O2: 300 providers trained. O3: Supply chain assured. O4: HMIS revised. | SOP approved by M6. Post-training pass rate ≥95%. Stock ≥95% across PHCs every Q. | DHO order copy; attendance records; PHC stock audits | Training time released; community accepts intervention. |
| Activities What you do |
SOP development · TOT cascade training · Procurement + buffer stock · Supportive supervision · KAP campaign. | Inputs / Budget: Personnel ₹38L · Training ₹14L · Procurement ₹22L · M&E ₹9L · Indirect ₹8.8L. Total ₹96.8 lakhs. | Quarterly progress reports; financial audit | Funds disbursed on schedule; political continuity. |
EU/FCDO 4×4 variant · exports as editable Word .doc with A4 margins
Live render of the actual certificate generator. Same HTML the engine emails on course completion. Logo, dual signatures, and QR code are real — the QR resolves to the live verification page when scanned.
URN Academy Certificate
Issued automatically when a learner completes all 4 levels of any URN Academy course (Research Methods · Data Analysis · HNA · AISRMA). Each carries a unique ID, dual signatures, and a QR code that resolves to a public verification page — so any employer or institution can confirm authenticity in one scan.
- Tier ladder — Bronze → Silver → Gold → Platinum (full course)
- Auto-emailed at every tier with a shareable SVG badge
- Public verification — anyone validates via QR or ID
- Lifetime validity — never expires
Tier Badges
Every URN Academy course has a 4-tier ladder. Bronze unlocks at Level 1; Silver after L1-2; Gold after L1-3; Platinum is the full Certificate of Completion. Each badge is auto-emailed as a shareable SVG — LinkedIn-ready, prints clean at any size.
- Auto-issued when you cross a level boundary
- Themed per course — Research Methods · Data Analysis · HNA · AISRMA
- SVG output — scales infinitely, opens in any browser
- Same engine as certificate — sample below: Dr Panda's progression
Bronze · Level 1
Foundations done
Silver · Levels 1-2
Screening done
Gold · Levels 1-3
Extraction & RoB done
The 4-tier progression
BRONZE
L1
SILVER
L1-2
GOLD
L1-3
PLATINUM
Certificate
Every course follows this ladder. Platinum unlocks the QR-verifiable Certificate of Completion.
Live SVG output from urnBadgeSVG() — same engine that emails badges when learners cross a level boundary
Directed Acyclic Graph (DAG)
A DAG is a picture of your causal hypothesis. Once it's on paper, the bias paths you must close become obvious — and the variables you must not adjust for (mediators) become equally obvious. The Suite produces these for every protocol.
- Exposure → Outcome — the causal effect you're estimating
- Confounders — cause both; must adjust
- Mediators — on the causal path; must not adjust if total effect is the target
- Colliders — adjusting opens bias; must avoid
- Backdoor criterion — the formal rule for which paths to block
Low-dose aspirin → pre-eclampsia, adjusting for maternal age + prior HTN. Placental blood flow is a mediator (don't adjust). Unmeasured genetic predisposition = residual backdoor — sensitivity analysis required.
= (1.96 √2·0.095·0.905 + 0.842 √0.12·0.88 + 0.07·0.93)² / (0.12 − 0.07)²
= (0.811 + 0.341)² / 0.0025 = ≈ 530 per arm
nadjusted = 530 / (1 − 0.15) = ≈ 624 per arm
Illustrative aspirin-in-pregnancy use case. The Suite plugs your numbers into the same formula and shows the working out — defensible at IEC review.
Sample Size Calculator
Plug in your expected effect, alpha, and power. Get the per-arm sample size with formula transparency — so the IEC reviewer can verify the math, and you can defend your number under questioning.
- Two-proportion test for binary outcomes
- Continuous outcomes — two-sample t-test mode
- Survival / time-to-event — log-rank test mode
- Dropout inflation automatically applied
Boolean Search Strategy
A reproducible search is the spine of every systematic review. Stack concept blocks with AND, expand each block with OR + MeSH + free-text — then translate to every database (PubMed, Embase, Cochrane CENTRAL, Scopus, Web of Science) without losing fidelity.
- One concept block per PICO element
- MeSH + Emtree + free-text in every block
- Truncation + wildcards for spelling variants
- Cross-database translation tracked + exported per PRISMA-S
("Pregnancy"[Mesh] OR pregnan*[tiab] OR gestation*[tiab] OR antenatal[tiab] OR "first pregnan*"[tiab]) AND ("Parity"[Mesh] OR nulliparous[tiab] OR nullipara*[tiab] OR primigravida*[tiab])
("Aspirin"[Mesh] OR aspirin[tiab] OR "acetylsalicylic acid"[tiab] OR ASA[tiab]) AND (low-dose[tiab] OR "60 mg"[tiab] OR "75 mg"[tiab] OR "81 mg"[tiab] OR "100 mg"[tiab] OR "150 mg"[tiab])
"Pre-Eclampsia"[Mesh] OR "Hypertension, Pregnancy-Induced"[Mesh] OR "pre-eclampsia"[tiab] OR "preeclampsia"[tiab] OR "pregnancy hypertension"[tiab] OR "gestational hypertension"[tiab] OR "HELLP"[tiab]
"Randomized Controlled Trial"[Publication Type] OR "randomized"[tiab] OR "randomised"[tiab] OR "controlled trial"[tiab] OR "placebo"[tiab] OR "double blind"[tiab] OR "Random Allocation"[Mesh]
Final hits · PubMed
2,847
Across 5 databases after dedup: 3,452 unique records
Reproducibility
Search: 14 March 2026 · Re-run: monthly · PRISMA-S checklist: 14/14 reported
Live preview from the AI SRMA Suite search builder. Concept-by-concept hit counts let you spot over- or under-coverage before submitting.
Eight outputs above — but a publishable systematic review needs more than tools. The next section is what makes the Suite different: a real methodologist, at every gate.
See the human support layerYou get a workspace and a methodologist — not just software.
Most AI SRMA tools hand you a dashboard and disappear. We do not. Every enrolment includes real human support from Dr. Paramjot Panda and the URN methodology team across every gate of your review — because tools without judgement produce confidently wrong systematic reviews.
The Technology
India's first AI-guided SRMA workspace built on Cochrane Handbook, PRISMA 2020, and GRADE foundations. Every step has a workbench, every workbench has a methodology gate.
- ▸ Topic Finalization Workbench — six-gate PROSPERO-readiness check (FINER + framework chooser + novelty statement)
- ▸ Search Strategy Builder — 10-database query generator + PRESS 2015 peer-review checklist
- ▸ AI Screening Co-pilot — title/abstract suggestions that learn from your decisions
- ▸ Cohen's κ live calculator — inter-rater reliability for dual screening, audit-passable
- ▸ RoB 2 / ROBINS-I / QUADAS-2 modules — auto-picked for your study design
- ▸ Meta-analysis engine — forest + funnel plots, I², τ², subgroup, sensitivity, publication-bias tests
- ▸ GRADE Evidence Profile Builder — Summary of Findings table you paste into your manuscript
- ▸ Manuscript drafter — section-by-section PRISMA 2020 scaffold
- ▸ PRISMA 2020 flow diagram — canonical four-box, export-ready
- ▸ Cohort + cohort-progress tracker — pause, resume, switch devices; nothing is lost
The Human Support
Software alone does not catch a fatal indirectness in your PICO at 11 PM the night before your PROSPERO submission. A methodologist does. You get one.
- ✦ 45-min 1:1 onboarding call with Dr. Paramjot Panda — we lock your topic + PICO together before you touch the platform
- ✦ Editorial review by Dr. Jyoti Ranjan Mohanty — Editor-in-Chief, UJHSE · reviews your manuscript for clarity, structure, and journal-fit before you submit
- ✦ Methodology review at every gate — submit your search strategy, your RoB judgements, your forest plot for a structured review (turnaround: 48 hours)
- ✦ WhatsApp support line — direct message us when you are stuck on a specific decision; we do not redirect you to a chatbot
- ✦ Weekly office-hour drop-ins — live Zoom for 8 weeks where you can join, watch others' problems, or ask your own
- ✦ Pre-submission manuscript review — methods + results sections read by a methodologist before you submit to a journal
- ✦ Journal-fit shortlist — we identify 3–5 target journals matched to your scope, scope and impact ambition
- ✦ Cover-letter draft + review — the right framing for editor-desk decisions
- ✦ Reviewer-response coaching — when (not if) reviewer comments arrive, we help you draft point-by-point responses
- ✦ Private cohort WhatsApp group — your peer cohort, your support network, your accountability
- ✦ Lifetime alumni access — we stay in touch long after submission; come back for your next review
Dr. Paramjot Panda
PhD (AIPH) · MPH (Manipal + Maastricht)
Systematic-review methodologist. Trains PG residents, MPH scholars, and faculty across 12+ Indian medical schools. Leads SRMA methodology gates + manuscript reviews.
Dr. Jyoti Ranjan Mohanty
Editor-in-Chief, UJHSE · State M&E Manager (HLFPPT–SSHAKTI / Global Fund)
15+ years public-health field experience across TB control, maternal & child health, nutrition, and WASH. Leads editorial review + journal-fit guidance. CRM & GCP certified.
Plus the URN methodology team — PG-level reviewers who handle screening sanity-checks, RoB second-opinions, and reviewer-response coaching alongside Dr. Panda and Dr. Mohanty.
From "I have an idea" to "I have a submitted manuscript"
A typical timeline. Faster if you can dedicate more hours per week; slower is fine too — your access is lifetime.
Onboarding call · lock your PICO · draft PROSPERO protocol · 1st methodology review with Dr. Panda
Build Boolean query · run 10 databases · PRESS 2015 peer-review · search-strategy review by methodologist
AI title/abstract triage · dual-screen + Cohen's κ · full-text retrieval · 2nd methodology review
Structured extraction · RoB 2 / ROBINS-I per study · methodologist sanity-check before synthesis
Forest plot · heterogeneity · subgroup · sensitivity · GRADE certainty · forest-plot review
Section-by-section drafting · PRISMA 2020 flow diagram · methods + results review by URN team
Journal-fit shortlist · cover-letter review · submission package check · reviewer-response coaching when comments arrive
Why pay Rs. 6,999 instead of going DIY
Launch offer is intentionally below cost — we want SRMA done right at scale in India. The Rs. 76,000 regular price returns once the launch window closes.
Before you decide
Is this an AI-only tool or do real humans review my work? +
What does "lifetime access" actually mean? +
Can I run more than one review on this? +
I am a PG resident with no prior SRMA experience. Is this for me? +
What if I get stuck mid-review and need help fast? +
Will you help me submit to a journal? +
Do you offer a refund? +
Get lifetime access today · ₹6,999
Regular price ₹76,000 after the launch window. One payment, unlimited reviews, forever.